Amgen sets plan for bone drug
- Share via
Times Wire Services
Amgen Inc. said it hoped to begin selling its bone drug denosumab next year, fueling growth as the decline in revenue from its top-selling anemia treatments bottoms out.
The company plans to file by the end of this year or early 2009 for U.S. approval of denosumab, Thousand Oaks-based Amgen has said.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
